Cardiff Oncology (NASDAQ:CRDF) Given New $17.00 Price Target at HC Wainwright

Cardiff Oncology (NASDAQ:CRDF) had its target price upped by analysts at HC Wainwright from $13.00 to $17.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 300.94% from the stock’s previous close.

Separately, Piper Sandler boosted their price target on Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th.

Cardiff Oncology Price Performance

CRDF stock opened at $4.24 on Friday. Cardiff Oncology has a 1-year low of $2.01 and a 1-year high of $6.42. The business has a fifty day moving average price of $4.06 and a 200-day moving average price of $3.24. The stock has a market capitalization of $216.81 million, a P/E ratio of -4.51 and a beta of 1.77.

Insider Transactions at Cardiff Oncology

In other Cardiff Oncology news, Director Gary W. Pace purchased 350,115 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was purchased at an average price of $2.60 per share, for a total transaction of $910,299.00. Following the completion of the purchase, the director now directly owns 1,047,876 shares of the company’s stock, valued at $2,724,477.60. This trade represents a 50.18 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 7.80% of the company’s stock.

Institutional Trading of Cardiff Oncology

Hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets purchased a new stake in Cardiff Oncology during the fourth quarter valued at $25,000. ProShare Advisors LLC purchased a new stake in Cardiff Oncology during the fourth quarter valued at $50,000. Raymond James Financial Inc. purchased a new stake in Cardiff Oncology during the fourth quarter valued at $56,000. Voya Investment Management LLC purchased a new stake in Cardiff Oncology during the fourth quarter valued at $57,000. Finally, Caxton Corp purchased a new stake in Cardiff Oncology during the fourth quarter valued at $58,000. Hedge funds and other institutional investors own 16.29% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.